Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.51 |
| ▸ | GSK3A | P49840 | 2/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.51 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.51 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.51 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | CSF1R | P07333 | 1/20 | 0.51 |
| ▸ | PRKACA | P17612 | 1/20 | 0.51 |
| ▸ | CDK2 | P24941 | 1/20 | 0.51 |
| ▸ | FLT4 | P35916 | 1/20 | 0.51 |
| ▸ | CLK2 | P49760 | 1/20 | 0.51 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.51 |
| ▸ | BRSK1 | Q8TDC3 | 1/20 | 0.51 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.51 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.51 |
| ▸ | SGK2 | Q9HBY8 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | AKT2 | P31751 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1460288 | 1.00 | GSK3B (0.51) | GSK3BGSK3AKDRCDK5DYRK1A | |
| SCHEMBL1226044 | 0.92 | CDK5 (0.59) | GSK3BGSK3AKDRCDK5DYRK1A | |
| SCHEMBL1460365 | 0.88 | MAPK14 (0.41) | GSK3BGSK3AKDRCDK5DYRK1A | |
| SCHEMBL1226655 | 0.87 | GSK3B (0.46) | GSK3BGSK3AKDRCDK5DYRK1A | |
| SCHEMBL1458522 | 0.87 | GSK3B (0.46) | GSK3BGSK3AKDRCDK5DYRK1A | |
| SCHEMBL1227181 | 0.86 | GSK3B (0.51) | GSK3BGSK3AKDRCDK5DYRK1A | |
| SCHEMBL1226707 | 0.86 | GSK3B (0.51) | GSK3BGSK3AKDRCDK5DYRK1A | |
| SCHEMBL1226653 | 0.86 | GSK3B (0.51) | GSK3BGSK3AKDRCDK5DYRK1A | |
| SCHEMBL1227564 | 0.86 | GSK3B (0.51) | GSK3BGSK3AKDRCDK5DYRK1A | |
| SCHEMBL1459139 | 0.86 | MAP2K4 (0.42) | GSK3BGSK3AKDRCDK5DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1435957-B1 | INHIBITORS OF GSK-3 AND CRYSTAL STRUCTURES OF GSK-3BETA PROTEIN AND PROTEIN COMPLEXES | VERTEX PHARMA (US) | 2009-06-17 | — | — | EP | claimed |
| US-7390808-B2 | Inhibitors of GSK-3 and crystal structures of GSK-3β protein and protein complexes | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-06-24 | — | — | US | claimed |
| US-20030125332-A1 | Inhibitors of GSK-3 and crystal structures of GSK-3 protein and protein complexes | VERTEX PHARMACEUTICALS INCORPORATED | 2003-07-03 | — | — | US | claimed |
| US-8318467-B2 | Inhibitors of GSK-3 and crystal structures of GSK-3β protein and protein complexes | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318467-B2 | Inhibitors of GSK-3 and crystal structures of GSK-3β protein and protein complexes | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-27 | — | — | US | disclosed |
| US-20110129896-A1 | INHIBITORS OF GSK-3 AND CRYSTAL STRUCTURES OF GSK-3Beta PROTEIN AND PROTEIN COMPLEXES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110129896-A1 | INHIBITORS OF GSK-3 AND CRYSTAL STRUCTURES OF GSK-3Beta PROTEIN AND PROTEIN COMPLEXES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-02 | — | — | US | disclosed |
| EP-2295550-A2 | Crystal structures of GSK-3beta protein and protein complexes and their use. | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-16 | — | — | EP | disclosed |
| US-7883881-B2 | Unphosphorylated glycogen synthase kinase-3-g-beta (GSK) from baculovirus overexpression system; competitive binding; diabetes, Alzheimer's disease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-02-08 | — | — | US | disclosed |
| US-7883881-B2 | Unphosphorylated glycogen synthase kinase-3-g-beta (GSK) from baculovirus overexpression system; competitive binding; diabetes, Alzheimer's disease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-02-08 | — | — | US | disclosed |
| US-7883881-B2 | Unphosphorylated glycogen synthase kinase-3-g-beta (GSK) from baculovirus overexpression system; competitive binding; diabetes, Alzheimer's disease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-02-08 | — | — | US | disclosed |
| EP-1435957-B1 | INHIBITORS OF GSK-3 AND CRYSTAL STRUCTURES OF GSK-3BETA PROTEIN AND PROTEIN COMPLEXES | VERTEX PHARMA (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-1435957-B1 | INHIBITORS OF GSK-3 AND CRYSTAL STRUCTURES OF GSK-3BETA PROTEIN AND PROTEIN COMPLEXES | VERTEX PHARMA (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20080262205-A1 | Inhibitors of GSK-3 and crystal structures of GSK-3beta protein and protein complexes | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080262205-A1 | Inhibitors of GSK-3 and crystal structures of GSK-3beta protein and protein complexes | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080262205-A1 | Inhibitors of GSK-3 and crystal structures of GSK-3beta protein and protein complexes | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-10-23 | — | — | US | disclosed |
| US-7390808-B2 | Inhibitors of GSK-3 and crystal structures of GSK-3β protein and protein complexes | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-06-24 | — | — | US | disclosed |
| US-7390808-B2 | Inhibitors of GSK-3 and crystal structures of GSK-3β protein and protein complexes | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-06-24 | — | — | US | disclosed |
| US-7390808-B2 | Inhibitors of GSK-3 and crystal structures of GSK-3β protein and protein complexes | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-06-24 | — | — | US | disclosed |
| US-20030125332-A1 | Inhibitors of GSK-3 and crystal structures of GSK-3 protein and protein complexes | VERTEX PHARMACEUTICALS INCORPORATED | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125332-A1 | Inhibitors of GSK-3 and crystal structures of GSK-3 protein and protein complexes | GSK3B, GSK3A, GSKIP | GSK3B 1/4885GSK3A 2/4885KDR 4612/4885 |
| US-20080262205-A1 | Inhibitors of GSK-3 and crystal structures of GSK-3beta protein and protein complexes | GSK3B, GSK3A, GSKIP | GSK3B 1/4885GSK3A 2/4885KDR 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.